CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2021 financial results will be released on Thursday, November 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 7525705
Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 7525705
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Fulcrum has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Please visit www.fulcrumtx.com.
Contact:
Naomi Aoki
Senior Vice President,
Corporate Communications and Investor Relations
naoki@fulcrumtx.com
Calgary, Alberta--(Newsfile Corp. - August 7, 2025) - Two Alberta innovators, PhantomOmics Inc. and Garden…
CE Certification positions SurgiBox for global expansion and robust sales acceleration CAMBRIDGE, Mass., Aug. 7,…
Headline Summary: Dr. Benjamin Stong, founder of Kalos Facial Plastic Surgery in Atlanta, was recently…
Acquisition integrates advanced AI-driven patient engagement and operational tools into HOPCo's expanding digital health and…
SANTA BARBARA, Calif., Aug. 7, 2025 /PRNewswire/ -- Every day, parents remind their kids: brush…
The Brain Computer Interface (BCI) market is experiencing rapid growth due to increasing advancements in…